{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:40:26Z","timestamp":1788961226330,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771765, 81701621"],"award-info":[{"award-number":["81771765, 81701621"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2019JJ40503"],"award-info":[{"award-number":["2019JJ40503"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-TIF1\u03b3 antibodies are a class of myositis-specific antibodies (MSAs) and are closely associated with adult cancer-associated myositis (CAM). The heterogeneity in anti-TIF1\u03b3+ myositis is poorly explored, and whether anti-TIF1\u03b3+ patients will develop cancer or not is unknown at their first diagnosis. Here, we aimed to explore the subtypes of anti-TIF1\u03b3+ myositis and construct machine learning classifiers to predict cancer in anti-TIF1\u03b3+ patients based on clinical features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort of 87 anti-TIF1\u03b3+ patients were enrolled and followed up in Xiangya Hospital from June 2017 to June 2021. Sankey diagrams indicating temporal relationships between anti-TIF1\u03b3+ myositis and cancer were plotted. Elastic net and random forest were used to select and rank the most important variables. Multidimensional scaling (MDS) plot and hierarchical cluster analysis were performed to identify subtypes of anti-TIF1\u03b3+ myositis. The clinical characteristics were compared among subtypes of anti-TIF1\u03b3+ patients. Machine learning classifiers were constructed to predict cancer in anti-TIF1\u03b3+ myositis, the accuracy of which was evaluated by receiver operating characteristic (ROC) curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-seven (54.0%) anti-TIF1\u03b3+ patients had cancer, 78.7% of which were diagnosed within 0.5\u00a0years of the myositis diagnosis. Fourteen variables contributing most to distinguishing cancer and non-cancer were selected and used for the calculation of the similarities (proximities) of samples and the construction of machine learning classifiers. The top 10 were disease duration, percentage of lymphocytes (L%), percentage of neutrophils (N%), neutrophil-to-lymphocyte ratio (NLR), sex, C-reactive protein (CRP), shawl sign, arthritis\/arthralgia, V-neck sign, and anti-PM-Scl75 antibodies. Anti-TIF1\u03b3+ myositis patients can be clearly separated into three clinical subtypes, which correspond to patients with low, intermediate, and high cancer risk, respectively. Machine learning classifiers [random forest, support vector machines (SVM), extreme gradient boosting (XGBoost), elastic net, and decision tree] had good predictions for cancer in anti-TIF1\u03b3+ myositis patients. In particular, the prediction accuracy of random forest was &amp;gt;90%, and decision tree highlighted disease duration, NLR, and CRP as critical clinical parameters for recognizing cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anti-TIF1\u03b3+ myositis can be separated into three distinct subtypes with low, intermediate, and high risk of cancer. Machine learning classifiers constructed with clinical characteristics have favorable performance in predicting cancer in anti-TIF1\u03b3+ myositis, which can help physicians in choosing appropriate cancer screening programs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.802499","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T02:15:42Z","timestamp":1644804942000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Machine Learning Algorithms Identify Clinical Subtypes and Cancer in Anti-TIF1\u03b3+ Myositis: A Longitudinal Study of 87 Patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Lijuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuoshan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuyu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Pi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and Management of Adult Inflammatory Myopathies","volume":"17","author":"Selva-O'Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of Specific Cancer Types in Dermatomyositis and Polymyositis: A Population-Based Study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202063260602","article-title":"Risk of Cancer in Patients With Dermatomyositis or Polymyositis. A Population-Based Study","volume":"326","author":"Sigurgeirsson","year":"1992","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00992","article-title":"Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer","volume":"8","author":"Aussy","year":"2017","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-12-200106190-00008","article-title":"Incidence of Malignant Disease in Biopsy-Proven Inflammatory Myopathy. A Population-Based Cohort Study","volume":"134","author":"Buchbinder","year":"2001","journal-title":"Ann Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1699","article-title":"Risk of Cancer in Patients With Dermatomyositis or Polymyositis, and Follow-Up Implications: A Scottish Population-Based Cohort Study","volume":"85","author":"Stockton","year":"2001","journal-title":"Br J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140566","article-title":"Polymyositis\/Dermatomyositis and Malignancy Risk: A Metaanalysis Study","volume":"42","author":"Yang","year":"2015","journal-title":"J Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2020.05.006","article-title":"Risk Factors and Cancer Screening in Myositis","volume":"46","author":"Moghadam-Kia","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"key":"B10","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in Myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2020.1791402","article-title":"Transcriptional Intermediary Factor 1 (TIF1) and Anti-TIF1gamma Antibody-Positive Dermatomyositis","volume":"44","author":"Kotobuki","year":"2021","journal-title":"Immunol Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez572","article-title":"Anti-TIF1-Gamma Autoantibodies: Warning Lights of a Tumour Autoantigen","volume":"59","author":"De Vooght","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04503-7","article-title":"The Spectrum and Clinical Significance of Myositis-Specific Autoantibodies in Chinese Patients With Idiopathic Inflammatory Myopathies","volume":"38","author":"Li","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.33379","article-title":"Usefulness of Anti-P155 Autoantibody for Diagnosing Cancer-Associated Dermatomyositis: A Systematic Review and Meta-Analysis","volume":"64","author":"Trallero-Araguas","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and Dermatomyositis (First of Two Parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of Multiple Cancer-Associated Myositis-Specific Autoantibodies in Idiopathic Inflammatory Myopathies: A Large Longitudinal Cohort Study","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134189","article-title":"Neutrophil Dysregulation Is Pathogenic in Idiopathic Inflammatory Myopathies","volume":"5","author":"Seto","year":"2020","journal-title":"JCI Insight"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.7.885","article-title":"Routine vs Extensive Malignancy Search for Adult Dermatomyositis and Polymyositis: A Study of 40 Patients","volume":"138","author":"Sparsa","year":"2002","journal-title":"Arch Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12564","article-title":"Meta-Analysis of the Association of Dermatomyositis and Polymyositis With Cancer","volume":"169","author":"Wang","year":"2013","journal-title":"Br J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab166","article-title":"A Systematic Review and Meta-Analysis to Inform Cancer Screening Guidelines in Idiopathic Inflammatory Myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14046","article-title":"Risk Factors for Cancer-Associated Myositis: A Large-Scale Multicenter Cohort Study","volume":"24","author":"Li","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key310","article-title":"Changes in Antibody Titres in Patients With Anti-Transcription Intermediary Factor 1-Gamma Antibody-Positive Idiopathic Inflammatory Myositis","volume":"58","author":"Abe","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B24","article-title":"Strong Correlation Between Cancer Progression and Anti-Transcription Intermediary Factor 1gamma Antibodies in Dermatomyositis Patients","volume":"36","author":"Ogawa-Momohara","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B25","first-page":"67","article-title":"Anti-Transcriptional Intermediary Factor 1 Gamma Antibodies in Cancer-Associated Myositis: A Longitudinal Study","volume":"38","author":"Dani","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101248","article-title":"Clinical and Serological Hallmarks of Systemic Sclerosis Overlap Syndromes","volume":"38","author":"Pakozdi","year":"2011","journal-title":"J Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2013(07)04","article-title":"Myositis-Specific and Myositis-Associated Autoantibody Profiles and Their Clinical Associations in a Large Series of Patients With Polymyositis and Dermatomyositis","volume":"68","author":"Cruellas","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e23307","DOI":"10.1002\/jcla.23307","article-title":"Analysis of Myositis Autoantibodies in Chinese Patients With Cancer-Associated Myositis","volume":"34","author":"Li","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.38093","article-title":"Most Patients With Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1gamma","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 Autoantibodies in Adult Patients With Idiopathic Inflammatory Myopathies: Possible Association With Malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/art.40895","article-title":"The Igg2 Isotype of Anti-Transcription Intermediary Factor 1gamma Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis","volume":"71","author":"Aussy","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170544","article-title":"Increased Levels of Soluble Programmed Death Ligand 1 Associate With Malignancy in Patients With Dermatomyositis","volume":"45","author":"Chen","year":"2018","journal-title":"J Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"R70","DOI":"10.1186\/ar2987","article-title":"Cancer Risks of Dermatomyositis and Polymyositis: A Nationwide Cohort Study in Taiwan","volume":"12","author":"Chen","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key357","article-title":"The Temporal Relationship Between Cancer and Adult Onset Anti-Transcriptional Intermediary Factor 1 Antibody-Positive Dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","article-title":"Anti-TIF1-Gamma Antibody and Cancer-Associated Myositis: A Clinicohistopathologic Study","volume":"87","author":"Hida","year":"2016","journal-title":"Neurology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283317fa5","article-title":"Paraneoplastic Myopathy","volume":"21","author":"Danko","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000641","article-title":"The Role of Cancer-Associated Autoantibodies as Biomarkers in Paraneoplastic Myositis Syndrome","volume":"31","author":"Lu","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"B38","article-title":"Incidence and Predictive Factors for Malignancies With Dermatomyositis: A Cohort From Southern China","volume":"32","author":"Chen","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04782-0","article-title":"Temporal Relationship Between Idiopathic Inflammatory Myopathies and Malignancies and Its Mortality: A Nationwide Population-Based Study","volume":"39","author":"Sung","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-019-00756-4","article-title":"Retrospective Analysis of Cancer-Associated Myositis Patients Over the Past 3 Decades in a Hungarian Myositis Cohort","volume":"26","author":"Andras","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.802499\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T02:15:49Z","timestamp":1644804949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.802499\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2022.802499"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.802499","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"article-number":"802499"}}